Vox Markets Interview with Avacta CEO Alastair Smith

Episode 1609  ·  Sep 19, 2023, 02:42 PM

Headliner
Share
Subscribe
Following today’s “stunning” safety & efficacy data wrt Avacta's AVA6000 phase 1a clinical trial, I was delighted to catchup again with CEO Alastair Smith, who took me through the hugely significant news.
Share
Subscribe
Next
‘Macro Investing’ masterclass with Chris Watling, Patrick Armstrong and Edmund Shing
Top episodes
Is a house price crash coming?
by The Vox Markets Podcast
Alastair Smith of Avacta: Successful Completion of Fourth Dose Escalation in AVA6000 Study
by The Vox Markets Podcast
Q&A with Belluscura CEO Bob Rauker & VP of global sales Bob Fary
by The Vox Markets Podcast